DSM and Codexis Sign Enzyme Supply Agreement
PARSIPPANY, N.J. and REDWOOD CITY, Calif., Jan. 12, 2011 - DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV, and Codexis, Inc. (Nasdaq:CDXS) today announce signing of an enzyme supply agreement.
The agreement grants DSM rights to use Codexis' custom biocatalysts and services, and secures supply of Codexis enzymes for commercialization of sustainable enzyme-based pharmaceutical manufacturing routes developed by DSM's InnoSyn(TM) route scouting services.
Codexis technology enables development of new efficient manufacturing processes for active pharmaceutical ingredients and intermediates which reduce cost and environmental waste. Codexis technology is used at major pharmaceutical and chemical companies worldwide including Merck, Pfizer and Teva.
The DSM InnoSyn(TM) route scouting team provides value creating solutions to its customer by integrating cutting edge enzyme technology with the full range of advances in synthetic methods such as homogeneous catalysis, modern organic synthesis and continuous chemistry, using for example micro reactors. The new routes result in increased efficiency of the manufacturing processes while reducing cost and environmental impact.
"Codexis has a proven track record over nearly 10 years in bringing innovation and manufacturing efficiency to our partners," said Joseph Sarret, M.D., President, Codexis Pharmaceutical Services & Enzyme Products. "We are pleased to collaborate with DSM in the field of biocatalysis to enable cost-effective manufacturing process at commercial scale."
Oliver May, Ph.D., Corporate Scientist and Business Manager for DSM's InnoSyn(TM) route scouting services commented: "One important success factor for implementing enzymatic routes is access to a diverse range of biocatalysts. DSM is continuously expanding its unique enzyme collection of more than 3000 enzymes by in-house developments as well as innovative partnering models. We are very pleased to collaborate with Codexis whose expertise in enzyme development perfectly matches with DSM's capabilities to identify, develop and implement efficient enzymatic routes."
Codexis
Codexis (Nasdaq: CDXS) is a clean technology company that develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with many leading global pharmaceutical companies and in development for advanced biofuels with Shell. Other potential markets include carbon capture, water treatment and chemicals. More information: www.codexis.com
DSM Pharmaceutical Products
DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: www.dsmpharmaceuticalproducts.com
DSM - the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel. DSM has annual net sales of about euro 8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com
SOURCE Codexis, Inc.
CONTACT: DSM, Oliver May, Ph.D., Business Manager, InnoSyn(TM), +31 (46) 4760551, oliver.may@dsm.com; or Media, Lyn Christenson, +1-650-421-8144, lyn.christenson@codexis.com, or Saskia Sidenfaden, +1-212-827-3771, ssidenfaden@mww.com, or Investors, Robert Lawson, +1-650-421-8137, robert.lawson@codexis.com, all of Codexis
